文献检索文档翻译深度研究
Suppr Zotero 插件Zotero 插件
邀请有礼套餐&价格历史记录

新学期,新优惠

限时优惠:9月1日-9月22日

30天高级会员仅需29元

1天体验卡首发特惠仅需5.99元

了解详情
不再提醒
插件&应用
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
高级版
套餐订阅购买积分包
AI 工具
文献检索文档翻译深度研究
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2025

替米沙坦介导的部分激活过氧化物酶体增殖物激活受体 γ 的结构基础。

Structural basis for telmisartan-mediated partial activation of PPAR gamma.

机构信息

Drug Discovery Research, Astellas Pharma Inc., Ibaraki, Japan.

出版信息

Hypertens Res. 2012 Jul;35(7):715-9. doi: 10.1038/hr.2012.17. Epub 2012 Feb 23.


DOI:10.1038/hr.2012.17
PMID:22357520
Abstract

Telmisartan, a selective angiotensin II type 1 receptor blocker, has recently been shown to act as a partial agonist for peroxisome proliferator-activated receptor gamma (PPARγ). To understand how telmisartan partially activates PPARγ, we determined the ternary complex structure of PPARγ, telmisartan, and a coactivator peptide from steroid receptor coactivator-1 at a resolution of 2.18 Å. Crystallographic analysis revealed that telmisartan exhibits an unexpected binding mode in which the central benzimidazole ring is engaged in a non-canonical--and suboptimal--hydrogen-bonding network around helix 12 (H12). This network differs greatly from that observed when full-agonists bind with PPARγ and prompt high-coactivator recruitment through H12 stabilized by multiple hydrogen bonds. Binding with telmisartan results in a less stable H12 that in turn leads to attenuated coactivator binding, thus explaining the mechanism of partial activation.

摘要

替米沙坦是一种选择性血管紧张素 II 型 1 型受体阻滞剂,最近已被证明能作为过氧化物酶体增殖物激活受体γ(PPARγ)的部分激动剂。为了了解替米沙坦如何部分激活 PPARγ,我们以 2.18Å 的分辨率确定了 PPARγ、替米沙坦和甾体受体共激活因子-1 的一个共激活肽的三元复合物结构。晶体学分析显示,替米沙坦表现出一种意想不到的结合模式,其中中央苯并咪唑环与 H12 (螺旋 12)周围的非典型(和非最佳)氢键网络结合。该网络与完全激动剂与 PPARγ 结合并通过多个氢键稳定 H12 从而促使高共激活剂募集时观察到的网络有很大不同。与替米沙坦的结合导致 H12 更不稳定,这反过来又导致共激活剂结合减弱,从而解释了部分激活的机制。

相似文献

[1]
Structural basis for telmisartan-mediated partial activation of PPAR gamma.

Hypertens Res. 2012-2-23

[2]
Distinct properties of telmisartan on agonistic activities for peroxisome proliferator-activated receptor γ among clinically used angiotensin II receptor blockers: drug-target interaction analyses.

J Pharmacol Exp Ther. 2014-1-14

[3]
Telmisartan downregulates angiotensin II type 1 receptor through activation of peroxisome proliferator-activated receptor gamma.

Cardiovasc Res. 2006-10-1

[4]
Characterization of telmisartan-derived PPARγ agonists: importance of moiety shift from position 6 to 5 on potency, efficacy and cofactor recruitment.

ChemMedChem. 2012-11

[5]
A selective peroxisome proliferator-activated receptor-gamma modulator, telmisartan, binds to the receptor in a different fashion from thiazolidinediones.

Endocrinology. 2009-2

[6]
Telmisartan inhibits vascular dysfunction and inflammation via activation of peroxisome proliferator-activated receptor-γ in subtotal nephrectomized rat.

Eur J Pharmacol. 2012-1-31

[7]
Design, synthesis, and docking studies of novel benzimidazoles for the treatment of metabolic syndrome.

J Med Chem. 2010-2-11

[8]
Telmisartan, a dual ARB/partial PPAR-γ agonist, protects myocardium from ischaemic reperfusion injury in experimental diabetes.

Diabetes Obes Metab. 2011-6

[9]
Telmisartan inhibits vasoconstriction via PPARγ-dependent expression and activation of endothelial nitric oxide synthase.

Cardiovasc Res. 2010-12-14

[10]
Characterization of new PPARgamma agonists: analysis of telmisartan's structural components.

ChemMedChem. 2009-3

引用本文的文献

[1]
Treatment of non-small cell lung cancer using chem-bioinformatics-driven engineering of exosomal cargo-vehicle for telmisartan and pioglitazone targeted-delivery.

Sci Rep. 2025-7-11

[2]
Differential expression of PPARγ by pioglitazone and telmisartan causes effect of disparity on mTORC2-mediated cell proliferation and migration.

Sci Rep. 2025-7-1

[3]
Cladosporols and PPARγ: Same Gun, Same Bullet, More Targets.

Biomolecules. 2024-8-13

[4]
Role of renin angiotensin system inhibitors and metformin in Glioblastoma Therapy: a review.

Cancer Chemother Pharmacol. 2024-7

[5]
Telmisartan metformin in downregulating myostatin gene expression and enhancing insulin sensitivity in the skeletal muscles of type 2 diabetic rat model.

Front Pharmacol. 2023-7-28

[6]
Pharmacological Utility of PPAR Modulation for Angiogenesis in Cardiovascular Disease.

Int J Mol Sci. 2023-1-25

[7]
PPARδ Agonist Promotes Type II Cartilage Formation in a Rabbit Osteochondral Defect Model.

Cells. 2022-9-20

[8]
PPARs and Myocardial Infarction.

Int J Mol Sci. 2020-12-11

[9]
Anti-Diabetic Effect of Telmisartan Through its Partial PPARγ-Agonistic Activity.

Diabetes Metab Syndr Obes. 2020-10-12

[10]
The PPAR Pocket: Renewed Opportunities for Drug Development.

PPAR Res. 2020-7-1

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

推荐工具

医学文档翻译智能文献检索